Supplemental insurance provider Aflac (NYSE: AFL) reported revenue ahead of Wall Street’s expectations in Q3 2026, but sales fell by 2.5% year on year to $4.30 billion. Its non-GAAP profit of $2.43 per share was 35.2% above analysts’ consensus estimates.

Is now the time to buy AFL? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Aflac’s third quarter performance was met with a positive market reaction, as results surpassed Wall Street’s revenue and non-GAAP profit expectations. Management attributed the quarter’s solid showing to ongoing strength in both the Japan and U.S. segments. In Japan, growth was supported by persistent demand for cancer and medical insurance, while the U.S. business saw momentum in its group life, disability, and network dental products. CEO Dan Amos highlighted that “Aflac U.S. generated a year-over-year 3.5% increase in sales for the third quarter,” driven by strategic expansion of its distribution channels and new product initiatives.

Looking ahead, management’s guidance is shaped by expectations of continued growth in supplemental insurance demand, disciplined underwriting, and capital redeployment initiatives. CFO Max Brodén indicated that future performance will be bolstered by further reinsurance activity and a strong capital position, stating, “We have meaningful runway to continue to execute further reinsurance transactions...to further improve the risk composition of Aflac Japan, and also enhance the overall capital position.” The company aims to leverage these capital releases for growth opportunities in both core markets and third-party reinsurance, while monitoring macroeconomic trends and maintaining prudent risk management.

Key insights from management’s remarks

Management focused on capital efficiency, product mix, and operational discipline as key themes in the quarter’s performance, while also outlining the impacts of recent leadership changes and reinsurance activity.

• Leadership succession planning: The company announced key executive changes effective January 2027, including promotions in both the Japan and U.S. businesses, reflecting a long-term strategy to ensure continuity and deep management experience.
• Japan reinsurance transaction: Aflac Japan ceded approximately 15% of its reserves to Aflac Re Bermuda, freeing up $1 billion in capital for redeployment. Management emphasized this as part of a broader effort to improve risk composition and return on equity through internal reinsurance, with a target of up to 30% of reserves eventually ceded.
• U.S. group business momentum: The U.S. segment achieved growth in group life, absence, disability, and network dental, with management noting that network dental sales increased 67% in the quarter. The strategy of cross-selling group products alongside voluntary benefits has been a major contributor to sales growth.
• Product mix shift in Japan: While third sector (cancer and medical) products remain the core, new products like Tsumitasu contributed 20% of total sales and are helping to attract younger customers. Management views this mix shift as beneficial for broadening the customer base and supporting sales to new demographics.
• Investment portfolio repositioning: The investment team executed large switch trades in Japan, moving $2.3 billion of assets to take advantage of higher interest rates. These actions are expected to improve net investment income by over $30 million annually and enhance portfolio quality.

Drivers of future performance

Aflac’s outlook is anchored in continued supplemental insurance demand, capital redeployment, and disciplined underwriting, with management monitoring macro trends and product mix shifts.

• Capital redeployment opportunities: Management sees further room for internal reinsurance between Aflac Japan and Aflac Re Bermuda, which is expected to enhance risk management and generate higher return on equity. The released capital may also be used for potential growth initiatives in core markets and third-party reinsurance.
• Product innovation and channel expansion: The company plans to continue developing products tailored to evolving customer needs, with a focus on cross-selling in the U.S. and leveraging diverse distribution channels in Japan. The Tsumitasu product and medical insurance offerings are expected to drive incremental sales, especially among younger demographics.
• Macroeconomic and regulatory risks: Management acknowledged ongoing pressure from rising healthcare costs and higher interest rates, particularly in Japan. The company is also closely watching claim trends in group disability and commercial real estate exposures in its investment portfolio, which could impact profitability if conditions worsen.

Catalysts in upcoming quarters

In the coming quarters, key factors to watch include (1) the pace of additional reinsurance transactions between Aflac Japan and Bermuda, (2) sustained growth in U.S. group and network dental products, and (3) the ongoing impact of product mix shifts, particularly Tsumitasu’s contribution in Japan. Continued capital deployment and responses to macroeconomic changes will also be key indicators of execution.

Aflac currently trades at $130.63, up from $125.30 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

Stocks that trumped tariffs

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.